e-learning
resources
Barcelona 2013
Sunday, 08.09.2013
Pulmonary circulation: animal models and experimental treatments
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Granulysin in pulmonary veno-occlusive disease
F. Perros, S. Cohen-Kaminsky, N. Gambaryan, B. Girerd, N. Raymond, I. Klingelschmitt, A. Huertas, O. Mercier, E. Fadel, G. Simonneau, M. Humbert, P. Dorfmüller, D. Montani (Le Kremlin-Bicêtre, Le Plessis-Robinson, France)
Source:
Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Session:
Pulmonary circulation: animal models and experimental treatments
Session type:
Poster Discussion
Number:
481
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
F. Perros, S. Cohen-Kaminsky, N. Gambaryan, B. Girerd, N. Raymond, I. Klingelschmitt, A. Huertas, O. Mercier, E. Fadel, G. Simonneau, M. Humbert, P. Dorfmüller, D. Montani (Le Kremlin-Bicêtre, Le Plessis-Robinson, France). Granulysin in pulmonary veno-occlusive disease. Eur Respir J 2013; 42: Suppl. 57, 481
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Th17 inflammation and pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014
Mitomycin-induced pulmonary veno-occlusive disease: Experience from the French pulmonary hypertension network
Source: International Congress 2015 – Pulmonary hypertension: rare and hereditary causes of PAH
Year: 2015
Inflammasome ASC-knock out attenuates the development of pulmonary hypertension caused by chronic alveolar hypoxia
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014
Pulmonary hypertension correction in patients with chronic obstructive pulmonary disease and essential hypertension
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014
Pulmonary hypertension associated with sarcoidosis
Source: Eur Respir Mon 2012; 57: 166-181
Year: 2012
Immune signatures in pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
Specific pulmonary arterial hypertension therapy in COPD patients with severe pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014
Characteristics of patients with pulmonary hypertension in end stage renal disease
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014
The incidence of chronic thromboembolic pulmonary hypertension secondary to acute pulmonary thromboembolism
Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension
Year: 2014
HbA1c-levels in patients with operable chronic thromboembolic pulmonary hypertension
Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension
Year: 2014
Global burden of chronic thromboembolic pulmonary hypertension (CTEPH): An epidemiological analysis
Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension
Year: 2014
Female pulmonary arterial hypertension is associated with decreased microRNA96 expression
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
The incidence of chronic thromboembolic pulmonary hypertension in asympthomatic pulmonary embolism patients
Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension
Year: 2014
Pulmonary hypertension complicating fibrosing mediastinitis
Source: International Congress 2016 – Clinic of pulmonary hypertension
Year: 2016
Immunity in idiopathic pulmonary arterial hypertension (IPAH), a role for activated DCs?
Source: International Congress 2016 – The nature of pulmonary hypertension
Year: 2016
Pulmonary veno-occlusive disease misdiagnosed as idiopathic pulmonary arterial hypertension
Source: Eur Respir Rev 2009; 18: 177-180
Year: 2009
Risk factors of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism
Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension
Year: 2014
Smad1 deficiency and female gender contribute to the development of pulmonary hypertension
Source: International Congress 2014 – Pathobiology of pulmonary hypertension
Year: 2014
Nebivolol and pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014
Endothelial-to-mesenchymal transition in pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept